Alyssa Johnsen, vice president and head of clinical development, Immunology and Fibrosis, shares her perspective on the great strides that have been made in the science of modulating the body’s immune response to treat disease. Alyssa started her career as a physician-scientist, where she was focused on understanding the pathophysiology of complex autoimmune diseases. During her career, Alyssa has contributed to advances that have helped deepen the understanding of common immune pathways, enabling rapid innovation and pipeline advancement.
Kellie Calderon, MD, executive medical director at Bristol Myers Squibb, has built her career in both clinical practice as well as in the pharmaceutical industry. Through her experiences, she has learned the value of collaboration and the importance of precision medicine — both of which are vital in advancing treatments and care for people living with immune-mediated diseases.
What excites you about the work that Bristol Myers Squibb is doing in immunology? And more specifically, rheumatology?
Subhashish Banerjee, MD, vice president & disease area head, Rheumatology and Dermatology at Bristol Myers Squibb, shares how the company is leveraging a pathways-based approach to advance research and ultimately elevate care for patients in need of new treatment options in systemic lupus erythematosus (SLE), also known as lupus.
Q: What is lupus and how does it impact patients’ lives?
“I never questioned my goal of becoming a Black neuroscientist because I had already met one, and for that, I am forever grateful,” said Kaelyn Brown, who first joined the Science Club for Girls (SCFG) at six years old. She continued the program throughout her youth, became a SCFG mentor during college and served as the co-director of the Harvard University Mentor Chapter. Recently graduating from Harvard with a degree in neuroscience, Brown credits her early exposure as critical to her pursuit of a career in science.
Long-term agreement will enable the continued development and eventual construction and operation of the Texas solar park that will annually power the equivalent of more than 37,000 average homes
HOUSTON, May 23, 2022 /3Bl Media/ -- EDP Renewables SA (EDPR), through its fully owned subsidiary EDP Renewables North America LLC (EDPR NA), and Bristol Myers Squibb (NYSE: BMY) have executed a 15-year power purchase agreement (PPA) for 60 megawatts (MW) at the 240-MW Cattlemen Solar Park in Milam County, located in central Texas.
How physicians, researchers and advocates are working towards this goal for patients
In his 15 years as a lung cancer specialist, Professor Nicolas Girard, MD, PhD, of the Curie-Montsouris Thorax Institute has seen – and helped advance – dramatic changes in how patients with this disease are treated. Yet despite this progress, lung cancer remains the leading cause of cancer deaths globally, and even patients who are diagnosed early often experience recurrence.
Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular disease. Learn more about HCM, its impacts and its symptoms.
Hypertrophic cardiomyopathy (HCM) is a chronic, inheritable disease where there is excessive thickening of the heart muscle. The most frequent cause of HCM is the presence of mutations in sarcomere protein genes. In its progressive form, HCM can lead to serious complications, including increased risk for atrial fibrillation, stroke, heart failure, and in rare cases, sudden cardiac death.
When a new “rash” appears on the skin, many people may not associate it with psoriasis. That was the case for Royce Thomas when he noticed what he thought was rash or a bug bite. Royce, senior territory business manager, Oncology at Bristol Myers Squibb, was familiar with various immune-mediated diseases, but never expected to be diagnosed with psoriasis, a widely prevalent, chronic, systemic immune-mediated disease that can substantially impair patients’ physical health, quality of life and work productivity.